Biotech | January 22, 2022
Lannett receives USFDA safety review for biosimilar insulin glargine
Go-ahead for pivotal clinical trial which is expected to commence by March
Go-ahead for pivotal clinical trial which is expected to commence by March
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
However, these won’t be available at the nearest chemist store soon
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
First launches expected in H1 2022
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Subscribe To Our Newsletter & Stay Updated
